Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Fiscon

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Frontiers in Immunology|July 24, 2023
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumorsSilvia Mezi, Giulia Pomati, Giulia Fiscon, et al.
Pigment Cell & Melanoma Research|June 1, 2025
Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World StudySilvia Mezi, Andrea Botticelli, Giulia Pomati, et al.
Cancers|September 28, 2023
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic MelanomaSilvia Mezi, Andrea Botticelli, Simone Scagnoli, et al.
Frontiers in Immunology|February 4, 2022
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor ActivityNicola Tumino, Francesca Besi, Stefania Martini, et al.
Cancers|October 23, 2021
Transcriptomics and Metabolomics Integration Reveals Redox-Dependent Metabolic Rewiring in Breast Cancer CellsMarcella Bonanomi, Noemi Salmistraro, Giulia Fiscon, et al.
Biomedicines|November 11, 2022
Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined ProfileSilvia Mezi, Giulia Pomati, Ilaria Grazia Zizzari, et al.
Cancer & Metabolism|October 2, 2020
Disruption of redox homeostasis for combinatorial drug efficacy in <i>K-Ras</i> tumors as revealed by metabolic connectivity profilingDaniela Gaglio, Marcella Bonanomi, Silvia Valtorta, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2023
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approachAndrea Botticelli, Alessio Cirillo, Giulia Pomati, et al.
Wiley Interdisciplinary Reviews. Systems Biology and Medicine|April 21, 2020
Molecular networks in Network Medicine: Development and applicationsEdwin K Silverman, Harald H H W Schmidt, Eleni Anastasiadou, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Frontiers in Immunology|July 24, 2023
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumorsSilvia Mezi, Giulia Pomati, Giulia Fiscon, et al.
Pigment Cell & Melanoma Research|June 1, 2025
Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World StudySilvia Mezi, Andrea Botticelli, Giulia Pomati, et al.
Cancers|September 28, 2023
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic MelanomaSilvia Mezi, Andrea Botticelli, Simone Scagnoli, et al.
Frontiers in Immunology|February 4, 2022
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor ActivityNicola Tumino, Francesca Besi, Stefania Martini, et al.
Cancers|October 23, 2021
Transcriptomics and Metabolomics Integration Reveals Redox-Dependent Metabolic Rewiring in Breast Cancer CellsMarcella Bonanomi, Noemi Salmistraro, Giulia Fiscon, et al.
Biomedicines|November 11, 2022
Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined ProfileSilvia Mezi, Giulia Pomati, Ilaria Grazia Zizzari, et al.
Cancer & Metabolism|October 2, 2020
Disruption of redox homeostasis for combinatorial drug efficacy in <i>K-Ras</i> tumors as revealed by metabolic connectivity profilingDaniela Gaglio, Marcella Bonanomi, Silvia Valtorta, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2023
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approachAndrea Botticelli, Alessio Cirillo, Giulia Pomati, et al.
Wiley Interdisciplinary Reviews. Systems Biology and Medicine|April 21, 2020
Molecular networks in Network Medicine: Development and applicationsEdwin K Silverman, Harald H H W Schmidt, Eleni Anastasiadou, et al.
Pageof 6